AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11168509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G/4G genotype
Number of subjects: 198
Study 11168509 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 activity
Number of subjects: 198
Study 9571222 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral dose of [14C]irbesartan
Number of subjects: 0
Study 9571222 — intervention group
Group type: COMPARATOR
Intervention: 900 mg nonradiolabeled doses of irbesartan
Number of subjects: 0
Study 9571222 — intervention group
Group type: EXPERIMENTAL
Intervention: [14C]irbesartan
Number of subjects: 0
Study 8299334 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for chest radiography dissemination
Number of subjects: 2500
Study 2455701 — intervention group
Group type: COMPARATOR
Intervention: CVP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Number of subjects: 177
Study 2455701 — intervention group
Group type: EXPERIMENTAL
Intervention: BACOP chemotherapy (3 cycles) followed by regional radiotherapy (40 to 50 Gy)
Number of subjects: 177
Study 30117122 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-Hz continuous theta burst stimulation (cTBS50)
Number of subjects: 17
Study 30117122 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-Hz continuous theta burst stimulation (cTBS30)
Number of subjects: 17
Study 28506118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh coconut (100 g)
Number of subjects: 58
Study 28506118 — intervention group
Group type: COMPARATOR
Intervention: Groundnuts and groundnut oil combination
Number of subjects: 58
Study 26564452 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized low-protein diet
Number of subjects: 40
Study 22932748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 22932748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21511226 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting Yukon Choice stent
Number of subjects: 240
Study 21511226 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting Taxus Liberté stent
Number of subjects: 240
Study 21511226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 240
Study 18305385 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69ST membrane
Number of subjects: 10
Study 18305385 — intervention group
Group type: EXPERIMENTAL
Intervention: FX100 membrane
Number of subjects: 10
Study 16879326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin and 50 mg of zinc acetate alone
Number of subjects: 46
Study 16879326 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin and 50 mg of zinc acetate in addition to metformin
Number of subjects: 46
Study 16879326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12884332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty-meal MRC
Number of subjects: 50
Study 12884332 — intervention group
Group type: COMPARATOR
Intervention: Control (no gallstones)
Number of subjects: 50
Study 11117656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 4016
Study 11117656 — intervention group
Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 4016
Study 8738538 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard bicarbonate hemodialysis
Number of subjects: 141
Study 8738538 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration
Number of subjects: 141
Study 8738538 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous hemofiltration
Number of subjects: 141
Study 8738538 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily recycled bicarbonate hemodialysis
Number of subjects: 141
Study 8738538 — intervention group
Group type: COMPARATOR
Intervention: Group I vs Group II
Number of subjects: 141
Study 8738538 — intervention group
Group type: COMPARATOR
Intervention: Within group comparison
Number of subjects: 141
Study 1452502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 1000 mg bd by constant infusion over 30 min
Number of subjects: 12
Study 1452502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 12
Study 1452502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms)
Number of subjects: 9
Study 6230176 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol (1.3 mg)
Number of subjects: 9
Study 6230176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31766216 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD: 250 mg) of Amarasate®
Number of subjects: 30
Study 31766216 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD: 100 mg) of Amarasate®
Number of subjects: 30
Study 31766216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29197999 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 449
Study 29197999 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 449
Study 26810338 — intervention group
Group type: EXPERIMENTAL
Intervention: 41 mg enoxaparin subcutaneously plus 81 mg aspirin daily pre‐conception
Number of subjects: 180
Study 26810338 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre‐conception
Number of subjects: 180
Study 24196347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage resection method (CRM)
Number of subjects: 77
Study 24196347 — intervention group
Group type: COMPARATOR
Intervention: Suturing method (SM)
Number of subjects: 77
Study 22064686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention designed to produce and maintain weight loss
Number of subjects: 28735
Study 20134098 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (high-dose group, 580 mg daily for 2 weeks)
Number of subjects: 30
Study 20134098 — intervention group
Group type: COMPARATOR
Intervention: Green tea catechins (medium-dose group, 80 mg daily for 2 weeks)
Number of subjects: 30
Study 20134098 — intervention group
Group type: COMPARATOR
Intervention: Green tea catechins (control group, 0 mg daily for 2 weeks)
Number of subjects: 30
Study 18802804 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive suppression task (random number generation)
Number of subjects: 0
Study 18802804 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression task
Number of subjects: 0
Study 15843109 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-based HIV/STI preventive intervention
Number of subjects: 388
Study 12699026 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 108
Study 12699026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 108
Study 12699026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment with Contingency Management (CBT + CM)
Number of subjects: 108
Study 12699026 — intervention group
Group type: COMPARATOR
Intervention: Methadone Maintenance
Number of subjects: 108
Study 10511320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Number of subjects: 0
Study 7718263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 84
Study 7718263 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 84
Study 1971445 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) 200 mg BID
Number of subjects: 24
Study 1971445 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Release (CR) 400 mg once daily
Number of subjects: 24
Study 433821 — intervention group
Group type: EXPERIMENTAL
Intervention: Two whole fresh eggs daily for 3 months
Number of subjects: 116
Study 433821 — intervention group
Group type: COMPARATOR
Intervention: Elimination of eggs for 3 months
Number of subjects: 116
Study 30717112 — intervention group
Group type: EXPERIMENTAL
Intervention: cyano‐B12 (2 × 0.76 µg)
Number of subjects: 67
Study 30717112 — intervention group
Group type: EXPERIMENTAL
Intervention: cow milk (2 × 200 mL)
Number of subjects: 67
Study 30717112 — intervention group
Group type: EXPERIMENTAL
Intervention: buffalo milk (2 × 200 mL)
Number of subjects: 67
Study 30717112 — intervention group
Group type: EXPERIMENTAL
Intervention: combined B12 index (cB12)
Number of subjects: 67
Study 28654131 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxybutynin 10% gel
Number of subjects: 61
Study 28654131 — intervention group
Group type: COMPARATOR
Intervention: Placebo compound
Number of subjects: 61
Study 26775474 — intervention group
Group type: EXPERIMENTAL
Intervention: Huikangling Tablet (HT), 0.4 g per tablet, 3 tablets each time, three times per day for 12 weeks
Number of subjects: 87
Study 26775474 — intervention group
Group type: COMPARATOR
Intervention: Control group (TSH suppression therapy only)
Number of subjects: 87
Study 23602345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1,200 mg
Number of subjects: 371
Study 23602345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 2,400 mg
Number of subjects: 371
Study 23602345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 3,600 mg
Number of subjects: 371
Study 23602345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 20862588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 28
Study 18455052 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter explaining the importance of influenza vaccine for HCW
Number of subjects: 800
Study 18455052 — intervention group
Group type: EXPERIMENTAL
Intervention: Raffle ticket activated with influenza vaccine administration for a free Caribbean vacation for 2
Number of subjects: 800
Study 18455052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both the educational letter and the raffle ticket
Number of subjects: 800
Study 18455052 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 800
Study 16821420 — intervention group
Group type: EXPERIMENTAL
Intervention: somatotropic therapy + coaxil (37.5 mg/day for 6 weeks; 25 mg/day for patients over 70 years)
Number of subjects: 376
Study 16821420 — intervention group
Group type: EXPERIMENTAL
Intervention: somatotropic therapy + coaxil
Number of subjects: 376
Study 16821420 — intervention group
Group type: COMPARATOR
Intervention: somatotropic therapy alone (control group)
Number of subjects: 376
Study 14571610 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Chinese and Western medicine (ICWM)
Number of subjects: 49
Study 14571610 — intervention group
Group type: COMPARATOR
Intervention: Control group (Western medicine)
Number of subjects: 49
Study 10737842 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (50 mg/kg per day for 7 days)
Number of subjects: 1217
Study 10737842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1217
Study 10737842 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 1217
Study 1578874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropylmethylcellulose (2%)
Number of subjects: 3
Study 1578874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (1%)
Number of subjects: 3
Study 1578874 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 3
Study 3905210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg/day orally)
Number of subjects: 9
Study 30696105 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) model
Number of subjects: 288
Study 30696105 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 288
Study 30696105 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) model
Number of subjects: 288
Study 30696105 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 288
Study 29799982 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle Aspiration (NA)
Number of subjects: 70
Study 29799982 — intervention group
Group type: COMPARATOR
Intervention: Chest Drain (CD)
Number of subjects: 70
Study 26576711 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin every 3 months for 3 years and 4 cycles of docetaxel plus estramustine
Number of subjects: 413
Study 26576711 — intervention group
Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 413
Study 24534125 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Internet psycho-educational training program for depression
Number of subjects: 298
Study 24534125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of automated Internet psycho-educational training program and Internet Support Group (ISG)
Number of subjects: 298
Study 24534125 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet Support Group (ISG)
Number of subjects: 298
Study 24534125 — intervention group
Group type: COMPARATOR
Intervention: Control website
Number of subjects: 298
Study 22534863 — intervention group
Group type: EXPERIMENTAL
Intervention: α-Galactosylceramide (α-GalCer)-pulsed antigen presenting cells (APCs)
Number of subjects: 4
Study 20548043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) plus standard medical care (SMC)
Number of subjects: 66
Study 20548043 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 66
Study 18579812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily
Number of subjects: 2531
Study 18579812 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 2531
Study 18579812 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2531
Study 18579812 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 2531
Study 15961004 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (LEV) - <or=6 nebs LEV 1.25 mg
Number of subjects: 140
Study 15961004 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (RAC) combined with ipratropium bromide (IB) - <or=3 nebs RAC 5.0 mg + IB 0.25 mg followed as needed by <or=3 nebs RAC 5.0 mg
Number of subjects: 140
Study 11972201 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium insufflation (group 3, n = 43)
Number of subjects: 173
Study 11972201 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium + saline lavage (group 4, n = 40)
Number of subjects: 173
Study 11972201 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation (group 1, n = 47)
Number of subjects: 173
Study 11972201 — intervention group
Group type: COMPARATOR
Intervention: CO2 + saline lavage (group 2, n = 43)
Number of subjects: 173
Study 11972201 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline peritoneal lavage (groups 2 and 4)
Number of subjects: 173
Study 10433013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-carbonic anhydrase II antibody testing in patients with PBC (n=40)
Number of subjects: 83
Study 10433013 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-carbonic anhydrase II antibody testing in patients with AIC (n=23)
Number of subjects: 83
Study 10433013 — intervention group
Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in healthy subjects (n=24)
Number of subjects: 83
Study 10433013 — intervention group
Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in patients with autoimmune hepatitis (n=10)
Number of subjects: 83
Study 10433013 — intervention group
Group type: COMPARATOR
Intervention: Anti-carbonic anhydrase II antibody testing in patients with obstructive jaundice (n=10)
Number of subjects: 83
Study 8754406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondialyzed (ND)
Number of subjects: 68
Study 8754406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent peritoneal dialysis (IPD)
Number of subjects: 68
Study 8754406 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 68
Study 8754406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 68
Study 8754406 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV)
Number of subjects: 68
Study 1387774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg orally once daily for 3-5 consecutive days
Number of subjects: 31
Study 6660847 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin combined with clavulanic acid (ACA)
Number of subjects: 41
Study 6660847 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 41
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with early termination of exclusive breastfeeding
Number of subjects: 484
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Having partners with formal education
Number of subjects: 484
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving counseling on exclusive breastfeeding at antenatal check-up
Number of subjects: 484
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Giving birth in a health institution
Number of subjects: 484
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiating breastfeeding within the first hour
Number of subjects: 484
Study 31711461 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving breast milk adequate for the first 6 months
Number of subjects: 484
Study 29289538 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids (OM3-CA) 2 g daily
Number of subjects: 162
Study 29289538 — intervention group
Group type: COMPARATOR
Intervention: Olive oil 2 g daily
Number of subjects: 162
Study 27091416 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 485
Study 27091416 — intervention group
Group type: COMPARATOR
Intervention: Control (patient's choice with physician's advice of low-dose cytarabine or supportive care)
Number of subjects: 485
Study 24957073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 69
Study 24957073 — intervention group
Group type: COMPARATOR
Intervention: Control (no cetuximab)
Number of subjects: 69
Study 22236405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with statins and fenofibric acid (FA)
Number of subjects: 1250
Study 22236405 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins and fenofibric acid (FA)
Number of subjects: 1250
Study 20351371 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling
Number of subjects: 15
Study 20351371 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling with bi-directional rotation
Number of subjects: 15
Study 20351371 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-directional needle rotation
Number of subjects: 15
Study 20351371 — intervention group
Group type: COMPARATOR
Intervention: Superficial needling
Number of subjects: 15
Study 16707736 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological intervention program
Number of subjects: 0
Study 16707736 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise program
Number of subjects: 0
Study 15718483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active device (1-microm absolute ceramic filter and ultraviolet light); used for 6 months in cycle A and then switched to sham device for 6 months in cycle B.
Number of subjects: 1296
Study 15718483 — intervention group
Group type: COMPARATOR
Intervention: Sham device; used for 6 months in cycle A and then switched to active device for 6 months in cycle B.
Number of subjects: 1296
Study 12001758 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical Wertheim‐Meigs hysterectomy with ovarian preservation
Number of subjects: 18
Study 12001758 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 patients with stage IB carcinoma of the cervix without accompanying pregnancy)
Number of subjects: 18
Study 10548322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fruit and -vegetable diet (9 daily servings)
Number of subjects: 29
Study 10548322 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 29
Study 7788650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 29
Study 7788650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 29
Study 7788650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 29
Study 1922868 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 0
Study 6753557 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg 3 times daily)
Number of subjects: 56
Study 6753557 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 56
Study 6753557 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (120 mg 3 times daily)
Number of subjects: 56
Study 6753557 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 56
Study 6753557 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 56
Study 30728074 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Shilajit (500 mg·d‐1)
Number of subjects: 63
Study 30728074 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Shilajit (250 mg·d‐1)
Number of subjects: 63
Study 30728074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 28068560 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate 300 mg/day plus aspirin 100 mg/day (SPG + ASA group)
Number of subjects: 40
Study 28068560 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day alone (ASA group)
Number of subjects: 40
Study 26091087 — intervention group
Group type: EXPERIMENTAL
Intervention: telephone-delivered cognitive behavioural treatment (CBT) for 8 weeks
Number of subjects: 80
Study 26091087 — intervention group
Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 80
Study 24919799 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling device treatment (3 treatments at 2-week intervals)
Number of subjects: 20
Study 24919799 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 20
Study 23390653 — intervention group
Group type: EXPERIMENTAL
Intervention: Original stimulating programs for correction of cognitive decline (computer programs, 20-30 minutes daily, 5 times a week for 14 days)
Number of subjects: 100